Mineralys Therapeutics Investor Relations Material

Mineralys Therapeutics Inc. (MLYS) is a clinical-stage biopharmaceutical company developing treatments for diseases associated with abnormally elevated aldosterone levels. The company's flagship product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, currently under investigation for its potential in treating hypertension. The company is headquartered in Radnor, Pennsylvania, and its shares are listed on the Nasdaq.